期刊
FRONTIERS IN NEUROLOGY
卷 8, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fneur.2017.00305
关键词
multiple sclerosis; anti-drug antibodies; interferon beta; enzyme-linked immunosorbent assay; biotherapy
资金
- Innovative Medicines Initiative [115303]
- European Union's Seventh Framework Program
- Hertie foundation [P1150063]
- Charcot foundation
Objective: To develop and validate a method for the detection of binding anti-drug antibodies (ADAs) against interferon beta (IFN-beta) in human serum as part of a European initiative (ABIRISK) aimed at the prediction and analysis of clinical relevance of anti-biopharmaceutical immunization to minimize the risk. Method: A two-tiered bridging enzyme-linked immunosorbent assay (ELISA) format was selected and validated according to current recommendations. Screening assay: ADA in serum samples form complexes with immobilized IFN-beta and biotinylated IFN-beta, which are then detected using HRP labeled Streptavidin and TMB substrate. Confirrnation assay: Screen putative positive samples are tested in the presence of excess drug (preincubation of sera with 0.3 mu g/mL of soluble IFN-beta) and percentage of inhibition is calculated. Results: The assay is precise, and the sensitivity of the assay was confirmed to be 26 ng/mL using commercially available polyclonal rabbit antihuman IFN-beta in human sera as the positive control. Conclusion: An ultrasensitive ELISA for IFN-beta-binding ADA testing has been validated. This will form the basis to assess anti-biopharmaceutical immunization toward IFN-beta with regards to its clinical relevance and may allow for the development of predictive tools, key aims within the ABIRISK consortium.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据